"I am thrilled to join Zosano at this exciting juncture in the company's growth," said Ms. Schulze. "The sheer volume of potential therapeutic programs utilizing Zosano's novel transdermal delivery technology represents a wealth of product development and lifecycle management opportunities, both from a proprietary pipeline and a partnership perspective. I look forward to working with our expanding team of highly talented scientists, physicians and business professionals to realize the commercial benefits of this promising technology."
Joining Peter Daddona, Ph.D., chief scientific officer; Greg Yedinak, vice president, manufacturing, and Kim Gaumer, vice president, regulatory affairs and quality assurance, are the following new members of Zosano's senior management team:
Don Brown, chief operating officer and president, brings more than 30 years of pharmaceutical experience to Zosano. Most recently, he served as senior executive vice president at Aventis Behring where he was a member of the Aventis SA Management Forum. Mr. Brown also held various senior leadership positions at U.S. Bioscience, and was a founder of Calvert Preclinical and Pharmaceutical Support services.
John M. Vuko, executive vice president and chief financial officer, has
extensive experience leading financial and administrative functions within
healthcare organizations. Prior to joining Zosano, Mr. Vuko was chief
financial officer at Genitope Corporation, a public company, which raised
more than $200 million in the public m
|SOURCE Zosano Pharma, Inc.|
Copyright©2008 PR Newswire.
All rights reserved